|
Pirfenidone (INN, BAN) is an anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II. It is a drug developed by several companies worldwide, including InterMune Inc. (now part of Roche), Shionogi Ltd., and GNI Group Ltd. In 2008, it was first approved in Japan for the treatment of IPF after clinical trials, under the trade name of Pirespa by Shionogi & Co. In October 2010, the Indian Company Cipla launched it as Pirfenex. In 2011, it was approved for use in Europe for IPF under the trade name Esbriet; it was approved in Canada in 2012 under the trade name Esbriet; and was approved in the United States in October 2014 under the same name. In September 2011, the Chinese State Food and Drug Administration provided GNI Group Ltd with new drug approval of pirfenidone in China, and later manufacture approval in 2013 under the trade name of Etuary.〔(【引用サイトリンク】 GNI Group receives manufacture approval for F647 from China FDA for first idiopathic pulmonary fibrosis drug in China )〕 In 2014 it was approved in Mexico under the name KitosCell LP, indicated for pulmonary fibrosis and liver fibrosis.〔kitoscelllp.com〕 There is also a topical form created for the treatment of abnormal wound healing processes.〔Coadjuvant treatment with surgery and pirfenidone in sever facial trauma due to dog bite. The journal of Craniofacial Surgery, volume 24, Number 2, March 2013〕 ==Medical uses== In Europe, pirfenidone is indicated for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. It was approved by the European Medicines Agency (EMA) in 2011.〔 In October 2008, it was approved for use in Japan, in India in 2010, and in China in 2011 (commercial launch in 2014). In October 2014, it was approved for sale in the United States. In Mexico it has been approved on a gel〔http://www.kitoscell.com〕 form for the treatment of scars and fibrotic tissue〔A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients, annals of plastic surgery, volume 68, number 1, january 2012〕 and has proven to be effective in the treatment of skin ulcers, such as diabetic foot. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Pirfenidone」の詳細全文を読む スポンサード リンク
|